By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Agendia BV 

Slotervaart Medical Centre, 9D
Louwesweg 6
Amsterdam    1066 EC  The Netherlands
Phone: 31-20-512-9161 Fax: 31-20-512-9162


SEARCH JOBS


Industry
Services
Healthcare






Company News
Agendia BV’s Mammaprint First And Only Genomic Assay To Receive Level 1A Clinical Utility Evidence For Chemotherapy Benefit In Early Breast Cancer Patients 4/19/2016 10:52:22 AM
Agendia BV To Highlight New MammaPrint Data At The 2016 European Breast Cancer Conference As A Prelude To Upcoming MINDACT Trial Findings 3/8/2016 10:34:04 AM
Agendia BV And Partners Receive $6.8 Million From European Commission (EC) To Study Targeted Therapies For Colorectal Cancer 12/16/2015 8:16:51 AM
Agendia BV Highlights Study Showing MammaPrint/BluePrint Tests Predict Response To Current Breast Cancer Chemotherapy And Targeted Therapy Regimens 9/29/2015 11:03:21 AM
Agendia BV Release: NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis 7/28/2015 10:20:51 AM
Agendia BV Co-Founder Wins European Inventor Award For Breast Cancer Test 6/16/2015 10:51:25 AM
Agendia BV Announces Recommendation Of MammaPrint In Germany’s AGO Guidelines, At St. Gallen International Breast Cancer Conference 4/8/2015 10:21:04 AM
Agendia BV Announces Recommendation Of Mammaprint In Germany’s AGO Guidelines, At St. Gallen International Breast Cancer Conference 4/7/2015 10:16:46 AM
Rubicon Genomics, Inc. And Agendia BV Renew Agreement For Use Of TransPLEX Whole Transcriptome RNA Amplification Kits With MammaPrint FFPE Breast Cancer Test 4/7/2015 6:29:12 AM
Agendia BV Receives New FDA Clearance for MammaPrint FFPE Breast Cancer Test 2/10/2015 6:21:04 AM
12345678910
//-->